Autopsy report · NCT00807755

Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors

“Number of known toxicities observed despite a treatment-naïve population”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 9 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

University of California, Davis

Sponsor type

University, hospital or other

Conditions

Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific

Interventions

Carboplatin; Etoposide; RAD001

Participants

5

Sites

1

Countries

United States

Trials that died the same way

• In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
  “Dose Limiting Toxicities” (64% match in meaning)
• Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
  “Inadequate toxicity” (63% match in meaning)
• A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
  “Extreme toxicity” (62% match in meaning)
• LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma
  “toxicity” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.